Trial Profile
Phase II trial: uPAR-PET/CT in Radium-223-dichloride treatment of patients with metastatic castration-resistant prostate cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Gallium-68 NOTA AE105 (Primary) ; Radium 223 chloride
- Indications Prostate cancer
- Focus Diagnostic use
- 11 Oct 2019 Status changed from suspended to discontinued.
- 28 Aug 2018 Planned End Date changed from 1 Jan 2019 to 1 Jun 2020.
- 28 Aug 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.